This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Poniard Announces Final Data From Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer

SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).  Dr. Tudor Eliade Ciuleanu, M.D., Ph.D., of Institute of Oncology, Cluj-Napoca, Romania and an investigator for the SPEAR trial, presented the data during an oral session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago, IL.

"Results from this important study show that picoplatin is an active compound, with a demonstrated survival benefit among patients where the use of post-study chemotherapy between treatment arms was balanced," stated Dr. Ciuleanu.  "These data include a number of significant outcomes, including improved overall survival among those individuals who did not receive post-study chemotherapy, the study's principal confounding factor, and among early relapsing or platinum refractory patients, a clinically meaningful population.  Further, picoplatin exhibits a manageable safety profile consistent with prior clinical experience. These results warrant further investigation in this indication."

"The SPEAR trial provides valuable insight into picoplatin's potential as an effective new treatment option for the vastly underserved early relapsing or platinum refractory SCLC patient population," said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals.  "These results are encouraging, both for Poniard and the oncologists addressing this difficult to treat disease. We continue to work toward establishing a path forward for picoplatin in this indication, as well as in other solid tumors where picoplatin has produced meaningful safety and efficacy data."    

SPEAR Trial Design

The international, multi-center, randomized, controlled Phase 3 SPEAR trial, one of the largest SCLC studies ever conducted, evaluated the efficacy and safety of picoplatin in 401 patients with SCLC who were refractory to or who progressed within six months of first-line platinum-based therapy. Picoplatin administered as an intravenous infusion once every three weeks plus best supportive care (BSC) was compared to BSC alone. BSC was designed in accordance with the National Comprehensive Cancer Network's guidelines. The primary endpoint of the trial was overall survival. Other endpoints included disease control rate, time to progression and progression-free survival (PFS). The trial was powered at 90 percent to show a 33 percent reduction in risk of death for picoplatin treatment plus BSC compared with BSC alone (hazard ratio of 0.67; p value of 0.05).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PARD $0.12 0.00%
AAPL $93.24 -0.41%
FB $118.15 0.08%
GOOG $699.84 0.60%
TSLA $213.20 -4.20%


Chart of I:DJI
DOW 17,697.25 +45.99 0.26%
S&P 500 2,055.71 +4.59 0.22%
NASDAQ 4,733.79 +8.1510 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs